Thanks for chasing this down. The marketing per
Post# of 30028
The marketing person says it's around the corner. The the study’s lead author says it's a ways off. It was a case control study. Have they publish the data for peer review. There may be literally dozens of companies in a similar situation that are very early on. It may very well work, but they have a lot of hurdles to go. If it was this simple, we would have launched Lympro a year ago and MANF this month.
Dr Kapogiannis emphasized that a blood test for AD is not around the corner .
"The emphasis should be on down the road because these are findings from case-control studies in a small number of patients and the findings need to be replicated and validated in larger studies, but still the findings are very clear cut and reached very high levels of statistical significance," he said.
http://www.medscape.com/viewarticle/835489
December 11, 2014 - "Researchers from the National Institute on Aging evaluated 174 patients with 100 percent accuracy using the new test as either Alzheimer’s disease or healthy. The California based company that created the test, NanoSomiX, said they plan to create a commercialized version of the test. The research was presented at the Society for Neuroscience conference in Washington in November."
“ We will need replication and validation , but I’m very optimistic this work will hold,” the study’s lead author Dimitrios Kapogiannis, MD, described to Bloomberg. “We were able to perfectly classify patients and controls.” -
Asked for comment on these findings, Dean M. Hartley, PhD, director of science initiatives at the Alzheimer's Association, told Medscape Medical News that the search for preclinical biomarkers of AD to facilitate early diagnosis is a "very active" area of research.
"A simple blood test that is performed in a doctor's office is certainly something we see as a direction of the future, but this is very much still in the research phase, " he said.
http://www.hcplive.com/articles/Blood-Sample-...s-Disease-